TRT and BPH: Does Testosterone Replacement Therapy Worsen Benign Prostatic Hyperplasia?

The Historical Fear: Why Clinicians Linked Testosterone to Prostate Growth

For decades, physicians assumed that raising testosterone levels would enlarge the prostate and worsen urinary obstruction. This fear traces back to Charles Huggins' 1941 Nobel Prize-winning work showing that castration caused prostate cancer regression and that androgen administration reactivated it [1]. The logic seemed straightforward: if removing testosterone shrank the prostate, adding it must make the gland grow.

That reasoning collapsed under modern scrutiny. Abraham Morgentaler's "saturation model," proposed in 2006 and supported by subsequent clinical data, demonstrated that prostate tissue androgen receptors become fully saturated at relatively low serum testosterone levels, around 230 ng/dL [2]. Above that threshold, additional testosterone does not proportionally stimulate further prostate growth. This explains why hypogonadal men brought into the normal range with TRT show only minimal prostate volume changes. A 2016 meta-analysis of 16 placebo-controlled randomized trials (N=3,565) published in The Journal of Urology found that testosterone therapy increased prostate volume by a mean of 1.5 mL, a difference that was statistically significant but clinically irrelevant [3]. The same analysis found no significant difference in IPSS between testosterone and placebo groups.

What the TTrials Revealed About Prostate Outcomes

The Testosterone Trials (TTrials) represent the largest coordinated set of randomized, placebo-controlled trials examining TRT outcomes in older men with low testosterone. The prostate sub-study enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL [4].

After 12 months of transdermal testosterone gel, mean prostate volume increased by 0.9 mL more than placebo, measured by MRI. That is roughly a 3.5% change from baseline. IPSS scores were not significantly different between groups [4]. Median PSA increased by 0.3 ng/mL in the testosterone arm, and no participant developed urinary retention or required prostate surgery during the trial.

These findings echoed a 2010 meta-analysis in European Urology (18 trials, N=3,167) that reported no statistically significant increase in urological events, including acute urinary retention, prostate surgery, or prostate cancer diagnosis, among men receiving testosterone compared with placebo [5]. The Endocrine Society's 2018 clinical practice guideline referenced both datasets when it softened its prior warnings, recommending TRT avoidance only in men with severe untreated LUTS (IPSS >19) or an unresolved palpable prostate nodule [6].

The Saturation Model: Why More Testosterone Does Not Mean More Prostate Growth

Morgentaler and Traish's saturation hypothesis fundamentally changed how urologists and endocrinologists think about androgens and the prostate. In a 2009 study published in European Urology, Morgentaler demonstrated that men with severe hypogonadism (testosterone <250 ng/dL) showed no significant change in prostate volume after being brought to eugonadal levels with TRT [7].

The molecular basis is straightforward. Prostate cells express a finite number of androgen receptors. Once circulating dihydrotestosterone (DHT), the primary intraprostatic androgen, occupies those receptors, additional testosterone provides no further growth stimulus. Intraprostatic DHT concentrations remain remarkably stable across a wide range of serum testosterone levels, as shown by Marks et al. In a 2006 randomized trial where prostate biopsies were obtained before and after 6 months of testosterone administration [8]. Tissue DHT, epithelial cell morphology, and biomarkers of cell proliferation were all unchanged compared with placebo.

This does not mean the prostate is entirely unresponsive. In profoundly hypogonadal men (post-castration levels, testosterone <50 ng/dL), restoration to normal range can produce measurable but modest volume increases [7]. The clinical question is not whether any change occurs, but whether it produces symptoms. The answer from every major randomized dataset published to date is no.

PSA Changes on TRT: What to Expect and When to Act

PSA monitoring remains a standard part of TRT oversight, and for good reason: testosterone stimulates PSA production by prostate epithelial cells. The typical trajectory is a rise of 0.3 to 0.5 ng/mL in the first 3 to 6 months, followed by a plateau [9]. The Endocrine Society recommends checking PSA at baseline, at 3 to 6 months, at 12 months, and then annually [6].

A referral for urological evaluation is warranted if PSA rises by more than 1.4 ng/mL within any 12-month period, if the absolute PSA exceeds 4.0 ng/mL (or 3.0 ng/mL in high-risk populations), or if a verified PSA velocity exceeds 0.75 ng/mL per year [6]. The American Urological Association (AUA) echoes these thresholds in its guidance on prostate cancer screening [10].

A 2023 systematic review in The Prostate examined PSA trajectories in 11 TRT studies (combined N=4,091) and confirmed that the initial rise stabilizes, with no progressive upward trend over 3 to 5 years of continuous therapy [11]. This plateau pattern aligns with the saturation model: once androgen receptors are occupied, PSA production reaches a ceiling.

One practical note: men starting TRT who have a pre-treatment PSA above 3.0 ng/mL should undergo urological evaluation before initiating therapy, not after. This is not because TRT will cause cancer, but because an elevated baseline PSA may indicate undiagnosed pathology that warrants investigation on its own merits [10].

TRT and Prostate Cancer: Separating Fear from Data

The relationship between TRT and prostate cancer risk has been the subject of intense study. A 2015 meta-analysis in Medicine pooling 22 randomized controlled trials (N=2,351) found no significant increase in prostate cancer incidence among men receiving testosterone compared with placebo (OR 0.87, 95% CI 0.30 to 2.50) [12].

The TRAVERSE trial (N=5,246), the largest randomized cardiovascular safety trial of TRT ever conducted, also tracked prostate outcomes as a secondary endpoint. Published in The New England Journal of Medicine in 2023, TRAVERSE found that the incidence of prostate cancer was similar between the testosterone and placebo arms over a mean follow-up of 33 months [13]. A dedicated prostate safety analysis from TRAVERSE, published in JAMA Network Open in 2024, confirmed that TRT did not increase rates of high-grade prostate cancer, prostate biopsies, or prostate-related procedures [14].

The Endocrine Society's 2018 guideline states that TRT is contraindicated in men with known metastatic prostate cancer and recommends careful risk-benefit discussion in men with a history of localized, treated prostate cancer [6]. For men without a cancer history, TRT does not appear to increase risk based on current evidence. The guideline explicitly notes that testosterone therapy "does not appear to increase the risk of prostate cancer" [6].

Erythrocytosis: The Side Effect That Actually Demands Attention

While prostate concerns dominate patient anxiety, the side effect that most frequently interrupts TRT is erythrocytosis, an elevation of hematocrit above 54% [15]. This occurs because testosterone stimulates erythropoietin production and directly activates erythroid progenitor cells in bone marrow [16].

Incidence varies by formulation. Injectable testosterone cypionate and enanthate produce supraphysiologic peaks that drive hematocrit higher than gels or patches. A 2017 pharmacokinetic study published in The Journal of Clinical Endocrinology & Metabolism reported erythrocytosis rates of 11.2% with injections versus 3.4% with transdermal preparations over 12 months [17]. The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months, 12 months, and annually thereafter [6]. If hematocrit exceeds 54%, the guideline advises dose reduction, formulation switch, or temporary discontinuation [6].

Elevated hematocrit increases blood viscosity. The TRAVERSE trial found a significantly higher rate of pulmonary embolism in the testosterone arm (0.9% vs. 0.5%), though the absolute difference was small and the overall rate of major adverse cardiovascular events (MACE) was not increased [13]. Donating blood is a commonly suggested workaround, but the evidence supporting therapeutic phlebotomy for TRT-induced erythrocytosis is anecdotal rather than trial-based [15].

Cardiovascular Risk on TRT: The TRAVERSE Verdict

The 2023 TRAVERSE trial put to rest years of conflicting data on TRT and cardiovascular safety. This FDA-mandated, randomized, double-blind, placebo-controlled trial enrolled 5,246 men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk [13].

The primary outcome was time to first MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). After a mean follow-up of 33 months, the hazard ratio was 0.96 (95% CI 0.78 to 1.17), meaning TRT did not increase MACE risk [13]. This result supersedes earlier observational studies that had raised concern, including a controversial 2013 JAMA study and a 2014 PLOS ONE analysis, both of which had significant methodological limitations [18].

The AHA issued a scientific statement in 2018 noting that the totality of evidence at the time was "insufficient to conclude that testosterone therapy increases or decreases cardiovascular risk" [19]. TRAVERSE has since shifted the consensus toward cardiovascular neutrality. One important caveat: TRAVERSE excluded men with recent acute coronary syndrome, NYHA class III-IV heart failure, and uncontrolled hypertension, so those populations still lack high-quality safety data [13].

Managing BPH Symptoms Concurrently with TRT

For hypogonadal men who already carry a BPH diagnosis, co-management is both possible and common. A 2019 retrospective cohort study in The Journal of Urology (N=1,023) found that men receiving both TRT and a 5-alpha reductase inhibitor (5-ARI) such as finasteride or dutasteride experienced stable IPSS scores and no increased rate of acute urinary retention over 4 years [20].

The pharmacological logic supports this combination. TRT raises serum testosterone, which 5-alpha reductase converts to DHT in the prostate. A 5-ARI blocks this conversion, reducing intraprostatic DHT by approximately 80 to 90% while allowing systemic testosterone benefits to persist [21]. Alpha-1 adrenergic blockers (tamsulosin, silodosin) can be added for immediate symptomatic relief of urinary hesitancy and frequency.

Men with moderate LUTS (IPSS 8 to 19) are generally considered appropriate candidates for TRT with concurrent BPH management. The Endocrine Society suggests a baseline IPSS, a urological consult if IPSS exceeds 19, and follow-up IPSS at 3 to 6 months after TRT initiation to confirm symptom stability [6]. A 2021 narrative review in Translational Andrology and Urology confirmed that well-managed BPH should not be considered a contraindication to TRT [22].

Monitoring Protocol: What Labs and Exams to Track

A structured monitoring plan reduces risk and catches problems early. The Endocrine Society's 2018 guideline outlines a clear schedule [6]:

Before starting TRT: Serum total testosterone (two morning samples), PSA, hematocrit, digital rectal exam (DRE), IPSS questionnaire, and lipid panel. Men with PSA above 3.0 ng/mL or an abnormal DRE should see a urologist before beginning therapy [6].

At 3 to 6 months: Repeat testosterone level to confirm adequacy, hematocrit, PSA, and IPSS. A PSA rise exceeding 1.4 ng/mL should prompt urological referral [6].

At 12 months and annually: Repeat the full panel: testosterone, hematocrit, PSA, DRE, IPSS, and metabolic markers including fasting glucose and lipids [6]. Bone mineral density testing (DEXA) is recommended at 1 to 2 years for men who had osteoporosis or low bone density at baseline [6].

This protocol is not TRT-specific paranoia. It reflects the same prostate and cardiovascular screening that the AUA and the U.S. Preventive Services Task Force (USPSTF) recommend for age-matched men regardless of hormone status [10]. TRT simply adds hematocrit and testosterone-level tracking to the standard preventive schedule.

TRT Side Effects Beyond the Prostate: A Brief Overview

While BPH and prostate cancer dominate the conversation, the full TRT side effect profile includes several other considerations. Acne and oily skin occur in roughly 15 to 25% of men, particularly with injectable formulations that produce supraphysiologic peaks [23]. Testicular atrophy results from hypothalamic-pituitary-gonadal axis suppression; exogenous testosterone reduces LH and FSH, shrinking the testes by 10 to 25% in volume over 6 to 12 months [6].

Fertility suppression is significant. TRT reduces sperm concentration by 50 to 90% in most men within 3 to 6 months, and some become azoospermic [24]. Men desiring future fertility should use alternatives such as clomiphene citrate, enclomiphene, or human chorionic gonadotropin (hCG) rather than exogenous testosterone [6].

Sleep apnea may worsen or emerge on TRT, though the data is mixed. The Endocrine Society lists untreated severe obstructive sleep apnea as a relative contraindication [6]. Gynecomastia, driven by aromatization of testosterone to estradiol, occurs in 10 to 25% of men and can be managed with dose adjustment or an aromatase inhibitor when clinically indicated [23].